Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Hazard Ratio01:12

Hazard Ratio

786
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
786
Crossover Experiments01:16

Crossover Experiments

3.4K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
3.4K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

1.7K
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis.

Journal of the National Cancer Institute·2026
Same author

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

Breast cancer research and treatment·2026
Same author

Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials.

Breast (Edinburgh, Scotland)·2026
Same author

Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer.

Frontiers in immunology·2026
Same author

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial.

Journal of the National Cancer Institute·2026

Related Experiment Video

Updated: May 6, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.1K

Clinical practice-changing trials: the HERA study paradigm.

Dimitrios Zardavas1, Felipe Ades, Evandro de Azambuja

  • 1Medical Oncology Department, Institut Jules Bordet, Br.E.A.S.T. Data Centre Brussels, Blvd de Waterloo, 121 (7th Floor), 1000 Brussels, Belgium.

Expert Review of Anticancer Therapy
|October 22, 2013
PubMed
Summary

The HERA trial demonstrated that trastuzumab significantly improves outcomes for early-stage HER2-positive breast cancer patients. This pivotal study established trastuzumab as a standard adjuvant therapy, changing the course of early breast cancer treatment.

More Related Videos

Virtual Prism Adaptation Therapy: Protocol for Validation in Healthy Adults
06:12

Virtual Prism Adaptation Therapy: Protocol for Validation in Healthy Adults

Published on: February 12, 2020

6.4K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.1K

Related Experiment Videos

Last Updated: May 6, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.1K
Virtual Prism Adaptation Therapy: Protocol for Validation in Healthy Adults
06:12

Virtual Prism Adaptation Therapy: Protocol for Validation in Healthy Adults

Published on: February 12, 2020

6.4K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.1K

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Trials

Background:

  • Trastuzumab is a humanized anti-HER2 monoclonal antibody targeting HER2-positive breast cancer.
  • Its efficacy in metastatic disease prompted investigation in the adjuvant setting.

Purpose of the Study:

  • To review the HERceptin Adjuvant (HERA) study, a pivotal trial for adjuvant trastuzumab.
  • To highlight the HERA study's contributions to treating early-stage HER2-positive breast cancer.

Main Methods:

  • The HERA trial randomized over 5000 patients.
  • Patients received 1-2 years of trastuzumab or observation post-chemotherapy.
  • Numerous substudies addressed specific clinical questions.

Main Results:

  • The HERA study proved trastuzumab alters the natural course of early HER2-positive breast cancer.
  • This trial led to the registration of trastuzumab for adjuvant therapy.
  • Subsequent analyses provided further insights into patient management.

Conclusions:

  • The HERA study established trastuzumab as a cornerstone of adjuvant therapy for HER2-positive breast cancer.
  • Lessons learned from HERA inform future treatment advancements.
  • International collaboration in HERA advanced the field of adjuvant breast cancer treatment.